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Glucose production during an IVGTT by deconvolution:
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Vicini, Paolo, Jeffrey J. Zachwieja, Kevin E. Yarash-
eski, Dennis M. Bier, Andrea Caumo, and Claudio
Cobelli. Glucose production during an IVGTT by deconvolu-
tion: validation with the tracer-to-tracee clamp technique.
Am. J. Physiol. 276 (Endocrinol. Metab. 39): E285–E294,
1999.—Recently, a new method, based on a two-compartment
minimal model and deconvolution [A. Caumo and C. Cobelli.
Am. J. Physiol 264 (Endocrinol. Metab.. 37): E829–E841,
1993; P. Vicini, G. Sparacino, A. Caumo, and C. Cobelli.
Comput. Meth. Prog. Biomed. 52: 147–156, 1997], has been
proposed to estimate endogenous glucose production (EGP)
from labeled intravenous glucose tolerance test (IVGTT)
data. Our aim here is to compare this EGP profile with that
independently obtained with the reference method, based on
the tracer-to-tracee ratio (TTR) clamp. An insulin-modified
(0.03 U/kg body wt infused over 5 min) [6,6-2H2]glucose-
labeled IVGTT (0.33 g/kg of glucose) was performed in 10
normal subjects. A second tracer ([U-13C]glucose) was also
infused during the test in a variable fashion to clamp
endogenous glucose TTR. The TTR clamp was quite success-
ful.As a result, the EGP profile, reconstructed from [U-13C]glu-
cose data with the models of Steele and Radziuk, were almost
superimposable. The deconvolution-obtained EGP profile,
calculated from [6,6-2H2]glucose data, showed remarkable
agreement with that obtained from the TTR clamp. Some
differences between the two profiles were noted in the esti-
mated basal EGP and in the initial modalities of EGP
inhibition. A high interindividual variability was also ob-
served with both methods in the resumption of EGP to
baseline; variability was high in both the timing and the
extent of resumption. In conclusion, the use of the two-
compartment minimal model of the IVGTT and deconvolution
allows the estimation of a profile of EGP that is in very good
agreement with that independently obtained with a TTR
clamp.
nonsteady state; mathematical model; tracer-to-tracee ratio;
specific activity clamp
THE LABELED INTRAVENOUS GLUCOSE TOLERANCE TEST
(IVGTT) is a powerful tool to estimate parameters
describing glucose metabolism in vivo, in normal and
disease states. In particular, it has recently been shown
that, if a two-compartment minimal model (2CMM) of
labeled glucose kinetics is used to describe the impulse
response of the glucose system, it is possible to obtain,
via deconvolution, a physiologically plausible profile of
endogenous glucose production (EGP) in normal hu-
mans during the IVGTT nonsteady state (4, 24), thus
eliminating the anomalies previously encountered when
a single-compartment minimal model was used (5).
This approach was also recently used with success in
normal subjects by Overkamp et al. (19). The ability of
reliably measuring EGP in nonsteady state is crucial to
investigate the modalities of glucose metabolism in
normal and disease states, and in particular to eluci-
date to what extent abnormal regulation of EGP contrib-
utes to the fasting hyperglycemia and carbohydrate
intolerance associated with non-insulin-dependent dia-
betes mellitus, obesity, and advancing age.
Validation of this deconvoluted profile of EGP by
means of direct measurement, i.e., the arteriovenous
(a-v) balance technique, is extremely difficult because
the a-v technique is easily applicable only in steady
state (26), where the Fick principle (13) is known to
hold. In all generality, assessment of EGP in nonsteady
state from tracer data must rely on a model of glucose
kinetics. However, modeling glucose kinetics in non-
steady state is difficult. General-purpose simplistic
models are in use (20, 22); however, as shown by
non-steady-state theory (6, 17), they introduce errors.
However, theory (6, 17, 18) also shows that, if the
glucose specific activity [or the tracer-to-tracee ratio
(TTR) for a stable isotope tracer (9)] is kept constant (or,
more realistically, its variations are minimized), one
can obtain a reliable estimate of EGP regardless of the
model used to describe non-steady-state glucose kinet-
ics (6, 18). Clamping glucose specific activity or TTR
during an IVGTT is very difficult, because the time
course of EGP, besides being unknown, is likely to
present noticeable and at least partly unpredictable
variations. A pioneering attempt along this line was
proposed in the dog by Cowan and Hetenyi (11), a study
in which the glucose system was prelabeled with a
primed, continuous infusion of tracer that was initiated
100 min before the labeled IVGTT and maintained
thereafter; in this way, specific activity reached a
constant value before the labeled IVGTT, and its
changes during the test were thus reduced.
In the present work, we use the TTR clamp technique
to validate the deconvolution method for reconstructing
EGP during an IVGTT. To do so, two tracers, [6,6-
2H2]glucose and [U-13C]glucose, were simultaneously
injected in the same subject and used to provide,
respectively, the deconvolution and the TTR clamp
EGP profile.
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EXPERIMENTAL DESIGN AND METHODS
Subjects and Protocol
Subjects. Five young men and five young women [age: 27 6
(SE) 7 yr, body weight: 62 6 3 kg] were studied after an
overnight fast. All were healthy, nonmedicated, nondiabetic,
in the normal range for height and weight, and free of
cardiovascular disease. Before participation, the subjects
received instructions from a research dietitian on how to
follow a weight-maintaining diet that provided $250 g of
carbohydrate on each of the 3 days leading up to an experi-
ment. During the day before an experiment, no exercise or
organized sport was allowed. All subjects received a detailed
description (both verbal and written) of the experimental
protocol, they were informed of potential risks, and written
informed consent was obtained. This study was approved by
the Washington University School of Medicine Institutional
Review Board.
Protocol
On the morning of an experiment the subjects were weighed
and, starting at 0800, a Teflon catheter was inserted into a
forearm vein of both arms, one for blood sampling and the
second for infusion of glucose and glucose isotopes. Patency of
the catheter used for blood sampling was maintained with a
slow drip of sterile saline. The study lasted a total of 6 h for
each subject (Fig. 1). After a baseline blood sample was
drawn, the subjects received a 2-h (0–120 min) primed (7
mg/kg), constant intravenous infusion (70 µg·kg2 ·min21) of
[U-13C]glucose to assess basal EGP. The pump used was a
Harvard variable-rate microprocessor-controlled motor-driven
syringe infusion pump (Pump 22, South Natick, MA). We
calibrated by pumping water at a set rate for a measured time
period and measured the weight and volume of the water
pumped. This agreed with the rate set on the pump. Also,
during the tracer infusion experiment, we marked the syringe
volume and clock time each time we changed the infusion
rate. We could then calculate the volume delivered over a
measured period of time (rate) during the actual experiment.
The second part of the experiment consisted of a 4-h
(120–360 min) IVGTT (330 mg/kg body wt of exogenous
glucose were administered as a bolus at 120 min) labeled with
the stable isotope [6,6-2H2]glucose (the concentration of pure
[6,6-2H2]glucose in the bolus was 10% of the unlabeled,
natural glucose content) and modified with insulin infusion.
In humans, the plasma glucose and insulin patterns after
glucose injection are quite similar. Therefore, it is difficult to
differentiate between the effects of glucose and insulin during
an IVGTT, and this ultimately results in increased variability
in the minimal model parameter estimates of insulin sensitiv-
ity and glucose effectiveness (25). Thus, we modified the
stable labeled IVGTT protocol to include a short-term insulin
infusion, so that the temporal patterns of glucose and insulin
became less similar. To do this, 0.03 U/kg of regular human
insulin (Novolin, Novo Nordisk, Princeton, NJ) was infused
for 5 min starting at minute 20 of the IVGTT. During the
IVGTT, [U-13C]glucose infusion continued, but the infusion
rate was this time adjusted in a stepwise fashion to mimic the
predicted pattern of EGP, thus keeping the TTR of [U-13C]glu-
cose (and thus of endogenous glucose) constant. A few pilot
experiments were allowed to adjust the stepwise infusion
(initially based on the results of Ref. 4), and the following
schedule was used (in percentages of basal rate): basal period,
100% of basal infusion rate; 0–2 min, 100%; 2–4 min, 80%;
4–6 min, 60%; 6–8 min, 40%; 8–10 min, 20%; 10–15 min,
10%; 15–30 min, 5%; 30–40 min, 20%; 40–50 min, 30%;
50–55 min, 40%; 55–60 min, 60%; 60–70 min, 80%; 70–80
min, 100%; 80–100 min, 110%; 100–120 min, 100%; 120–160
min, 90%; 160–240 min, 80%. In the event that a blood
sample and change in infusion rate occurred at the same time
point, blood sampling preceded the change in infusion rate.
Blood samples were obtained at 0, 2, 3, 5, 8, 10, 15, 20, 30,
45, 60, 75, 90, 100, 110, and 120 min during the first part of
the experiment and at 122, 123, 124, 125, 126, 128, 130, 132,
134, 136, 139, 142, 144, 146, 148, 150, 155, 160, 165, 170, 175,
180, 190, 200, 220, 240, 260, 280, 300, 330, and 360 min
during the IVGTT. Total glucose, plasma insulin, and the
complete mass spectra for [U-13C]glucose and [6,6-2H2]glucose
were measured from each sample.
Methods
Measurements. Blood samples for glucose and insulin were
collected in heparinized tubes. All samples were immediately
placed on ice, and after centrifugation, plasma was stored at
280°C for insulin and glucose tracer analysis. Plasma glucose
concentration was determined at bedside by the glucose
oxidase method using a Beckman Glucose Analyzer (Beck-
man Instruments, Fullerton, CA), and plasma insulin was
determined by radioimmunoassay (16). A portion of each
plasma sample was deproteinized in cold acetone. After
centrifugation, the supernatant was removed and evapo-
rated, and the pentaacetate derivative of glucose was formed
by the addition of 100 µl of acetic anhydride-pyridine (1:1).
Glucose was separated by gas chromatography at 180°C on a
3% OV 101 column, and 2H and 13C isotopic abundance was
measured by positive chemical ionization mass spectrometry
by use of selected ion monitoring of peak intensities at
mass-to-charge ratios 331, 332, 333, 334, 335, 336, and 337.
The [U-13C]glucose tracer (99 atom%) was manufactured by
Isotec (Miamisburg, OH), and the [6,6-2H2]glucose tracer (99
atom%) was manufactured by MassTrace (Woburn, MA). The
gas chromatography-mass spectrometer (GC-MS) characteris-
tics and manufacturer were Finnigan 3300 GC-quadru-
pole-MS (Sunnyvale, NY).
Fig. 1. Experimental protocol. Each subject received simultaneously
a variable [U-13C]glucose infusion (A) and a [6,6-2H2]glucose-labeled
intravenous glucose tolerance test (IVGTT, B).
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The TTR of [6,6-2H2]glucose [ZI(t)] and [U-13C]glucose
[ZII(t)] at each sampling time t were calculated from the peak
ratio data by using an extension of the case of multiple labels
of the formulas in Refs. 8–10. From the TTRs, ZI(t) and ZII(t)
and total glucose G(t), one can derive the concentrations of
exogenous glucose injected with the [6,6-2H2]glucose-en-
riched bolus in the sample
CI(t ) 5
G(t )Z I (t )
1 1 ZI(t ) 1 ZII (t ) (1)
and of exogenous glucose injected with the [U-13C]glucose-
enriched bolus
CII (t ) 5
G(t )Z II (t )
1 1 ZI(t ) 1 ZII (t )
(2)
In the following explanation, we will refer to [6,6-2H2]glucose
and [U-13C]glucose concentrations, meaning by this the ‘‘total
exogenous concentration’’ injected with these tracers, in
keeping with an established formalism (1, 9, 10, 23, 24).
Endogenous glucose, i.e., the portion of plasma glucose
concentration attributable to EGP, was calculated from ZI(t),
ZII(t), and total glucose concentration G(t) (7, 9)
Ge(t ) 5 G(t ) 2 CI(t ) 2 CII (t ) 5
G(t)
1 1 ZI(t ) 1 ZII (t )
(3)
The measurement error associated with all these variables
was directly derived via error propagation by use of an
extension of the formulas described in Refs. 1 and 10.
EGP estimation from the TTR clamp. From non-steady-
state theory (6, 17, 18) we can see that, if the TTR in the
accessible compartment is kept constant, ZII(t) 5 ZII, all
peripheral compartments that exchange material with the
accessible compartment will have the same TTR as the
accessible compartment and EGP can be calculated in a
model-independent way as follows
EGP(t ) 5
Ra* (t)
ZII
(4)
EGP(t) is thus equal to the known time-varying tracer
infusion rate R*a(t), apart from the scale factor given by the
constant TTR. It is, however, quite difficult, in practice, to
maintain the TTR perfectly constant throughout the experi-
ment, and EGP(t) estimation still requires a model. Neverthe-
less, by keeping the variations of ZII(t) small, one greatly
enhances the accuracy of the model reconstruction of EGP
and makes it much less dependent on the validity of the
model used. Because in our experiment the TTR clamp was
quite good (in Fig. 2 it can be seen how [U-13C]glucose
concentration profile in plasma closely followed that of endog-
enous glucose), we were confident that the non-steady-state
error was minimized and that determination of EGP was
almost model independent. As a matter of fact, the estimates
of EGP provided by models of Steele (22) and Radziuk et al.
(20), i.e., the two models that are widely used to perform
non-steady-state analysis, were almost identical (as we will
show later on). We chose the EGP profile calculated with
Radziuk’s two-compartment model because it is more accu-
rate than Steele’s model (6, 20). Specifically, we adopted the
version of Radziuk’s model with only one time-varying irre-
versible loss from the accessible compartment (20), because it
allows us to express the unknown EGP with a simple formula
(see APPENDIX A for details)
EGP(t ) 5
Ra* (t )
ZII (t )
2
V1Ge(t )
ZII (t )
dZII (t )
dt
1 k12 3 q 2
* (t )
ZII (t )
2 q2 (t ) 4 (5)
where V1 is the volume of the accessible pool (dl/kg), and q2
denotes the endogenous glucose mass in the second compart-
ment (mg/kg). Still, although all of the elements in Eq. 5 can
be directly evaluated from data, which makes it particularly
appealing, experimental noise can jeopardize some calcula-
tions, especially the first derivative of ZII(t), which is evalu-
ated at the midpoint of each sampling integral via finite
differences. For this reason, both endogenous glucose and
TTR data were smoothed by using a three-samples moving
average. In this fashion, we set forth to calculate for each
subject a time course of EGP that is likely to be reliable and
can then be used as a reference for validation purposes. Note
that EGP(t) is also evaluated at the midpoint of each sam-
pling interval.
EGP estimation by deconvolution. We refer to APPENDIX A
for details on the 2CMM and the deconvolution approach to
estimate EGP. Briefly, the relation between EGP (input) and
Fig. 2. Mean tracer-to-tracee ratio (TTR) clamp plasma data. A:
endogenous glucose concentration; B: [U-13C]glucose concentration;
C: endogenous glucose TTR (ZII).
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endogenous glucose concentration Ge (output) during an
IVGTT can be described by the integral equation
Ge(t ) 5 e0
t
h( t,t)EGP(t) dt 1 Gb (6)
where Gb is baseline glucose concentration, and h(t,t) is the
time-varying kernel of the glucose system described by the
2CMM identified from [6,6-2H2]glucose data. Details of the
procedure used for estimation of EGP are reported in Refs. 12
and 24. We wish to point out that Eq. 6 is a Fredholm integral
equation of the first kind, but we use here the term ‘‘deconvo-
lution’’ [rigorously applicable only when the kernel h(t,t) is
time invariant] both for the sake of simplicity and in keeping
with the existing literature (4, 24). EGP is estimated by the
following formula
EGP 5 ( HTB21H 1 gFTF )21 HTB21 DGe 1 EGPb (7)
where H is the system matrix, F is an appropriately chosen
regularization matrix (chosen according to the desired degree
of smoothness of the EGP estimate; see Refs. 12, 21, and 24
for details), DGe is the deviation of endogenous glucose from
baseline, B is the (diagonal) matrix of measurement errors
associated with endogenous glucose samples, EGPb is basal
EGP, and g is a regularization parameter.
RESULTS AND DISCUSSION
Basal pretest plasma glucose was 88 6 6 (SE) mg/dl,
and basal pretest plasma insulin concentration was 4 6
1 µU/ml. Mean plasma [U-13C]glucose concentration
(CII) and endogenous glucose TTR (ZII) are shown in
Fig. 2, together with endogenous glucose concentration
(Ge). Mean plasma glucose (G), insulin (I), and [6,6-
2H2]glucose concentrations (CI) are shown in Fig. 3.
TTR Clamp
Model parameters (V1, k21, k12, k01) were estimated
for each subject (Table 1) by weighted nonlinear least
squares from the data of the primed, constant infusion
of [U-13C]glucose during the baseline period of 0–120
min. Weights were chosen optimally, i.e., equal to the
inverse of the measurement error variance (3). The
measurement error associated with the tracer measure-
ments was assumed to be independent, white, Gauss-
ian, with mean zero and a variance generated by error
propagation from the peak ratio measurement error
variance (10) and ranged between 6 and 10% (higher for
lower concentration values). Peak ratio standard devia-
tions were determined via replicate measurements.
Equation 5 was then applied to the data, and the
average profile of EGP is shown in Fig. 4.
A rapid and almost complete suppression of EGP was
seen only 10–15 min after the glucose challenge and
between 20 and 40 min EGP increased rapidly. In this
period (120–160 min of the experimental protocol), the
TTR clamp was quite good, and we believe that this
constitutes evidence that our estimate of EGP is sub-
stantially correct, because it means that the shape of
EGP during that time closely agreed with that of the
variable [U-13C]glucose infusion. Clamping TTR be-
tween 200 and 360 min was, however, much more
Fig. 3. Mean labeled IVGTT plasma concentration data. A: glucose;
B: [6,6-2H2]glucose; C: insulin.
Table 1. Parameter values of model of Radziuk et al.
(20) identified from data of primed, constant infusion
of [U-13C]glucose during baseline period
Subject
No.
V1,
dl/kg
k21,
min21
k12,
min21
k01,
min21
1 1.150 (10) 0.0830 (76) 0.0980 (126) 0.0322 (32)
2 1.538 (3) 0.0312 (15) 0.0495 (18) 0.0169 (5)
3 1.664 (2) 0.0504 (12) 0.0711 (13) 0.0178 (4)
4 1.093 (20) 0.1430 (56) 0.1156 (37) 0.0219 (26)
5 1.837 (10) 0.0209 (95) 0.0559 (116) 0.0179 (19)
6 1.567 (21) 0.0317 (95) 0.0467 (102) 0.0116 (47)
7 1.534 (9) 0.0223 (59) 0.0373 (96) 0.0228 (20)
8 1.246 (12) 0.0495 (50) 0.0591 (54) 0.0253 (17)
9 2.073 (7) 0.0052 (241) 0.0107 (645) 0.0125 (142)
10 1.830 (6) 0.0240 (62) 0.0823 (55) 0.0163 (9)
Mean
6SE 1.55360.100 0.046160.0127 0.062660.0096 0.019560.0020
Values are parameter estimates. Numbers in parentheses are
estimate precisions expressed as percent coefficient of variation
(%CV). V1, volume of glucose accessible pool; k21, k12, k01, glucose
kinetic parameters.
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difficult, because the time of resumption of EGP varied
among the subjects. Moreover, when both tracer and
endogenous glucose concentrations are very low, such
as during maximal inhibition, the time course of the
TTR is very sensitive to changes in both tracer and
glucose concentration. Therefore, if a small increase in
endogenous glucose concentration is not accompanied
by a concomitant increase in the tracer concentration
(as dictated off-line by the exogenous infusion), this
would induce a noticeable decrease in the TTR. Now,
the problem is to determine in some way to what extent
these problems related to the TTR clamp introduced an
error in our estimate of EGP between 200 and 360 min.
As a possible approach to at least partially assess the
magnitude of this error, we compared EGP calculated
with the model of Steele (22) (setting the volume of the
glucose compartment equal to 1.3 dl/kg body wt and
individualizing the basal value of the irreversible,
time-varying loss from this volume and plasma clear-
ance rate) with that of the model of Radziuk et al. (20).
In fact, because theory shows (6) that the error affect-
ing EGP estimation depends on both the model used for
non-steady-state glucose kinetics and the rate of change
of the TTR, the difference between the models of
Radziuk et al. and Steele (i.e., between a good and a
poor model of non-steady-state glucose kinetics) pro-
vides some insight on the influence of the TTR changes
on the estimate of EGP. The time courses of EGP thus
derived were almost superimposable (Fig. 4); therefore,
despite an imperfect clamp of specific activity, it is
possible to conclude that the EGP estimate calculated
between 200 and 360 min is reliable.
The sudden up-and-down performance of EGP ob-
served with both models in the first 10 min of the
IVGTT is unlikely to be representative of a true physi-
ological occurrence. Rather, it is probably a symptom of
the marked ill-conditioning affecting EGP estimation
in that portion of the IVGTT. We speculate that, even in
the presence of a good TTR clamp and data smoothing,
when sampling is very frequent and the tracer infusion
rate is frequently changed, as in the initial part of the
IVGTT, even very small errors in the evaluation of the
TTR derivative are uncontrollably amplified and deter-
mine spurious oscillations in the deconvolved profile.
Deconvolution
The uniquely identifiable parameters of the 2CMM
were estimated from [6,6-2H2]glucose data by weighted
nonlinear least squares as described in Ref. 24. The
model was identified in all subjects (Table 2). The
measurement error coefficient of variation (CV) of
[6,6-2H2]glucose concentration data ranged from 2.3 to
12.6% on average, with lower precision associated with
lower concentration values. The mean EGP time course
estimated by deconvolution is shown in Fig. 5 together
with that obtained with the TTR clamp (mean 6 SE).
We can see that, on average, there is a very good
accordance between the two estimates. EGP is almost
completely inhibited already at 140 min, and early in
the test it clearly shows a bimodal pattern, probably
caused by the insulin injection between 140 and 145
min [a plot of the average insulin action x(t) estimated
by the model is shown in Fig. 6]. The exogenous insulin
administration results then in a new suppression of EGP,
Table 2. Two-compartment minimal model parameters identified from IVGTT data of [6,6-2H2]glucose data with
assumption of insulin and glucose plasma concentrations as known inputs
Subject
No.
V1,
dl/kg
k21,
min21
k12,
min21
k02,
min21
p2,
min21
sk,
ml·min21 ·µU21
1 2.47 (20) 0.042 (16) 0.338 (24) 0.0233 (207) 0.0672 (24) 0.0185 (229)
2 1.71 (4) 0.038 (15) 0.024 (39) 0.0018 (21) 0.1886 (21) 0.0025 (82)
3 2.53 (3) 0.030 (11) 0.069 (37) 0.0055 (27) 0.3930 (57) 0.0069 (71)
4 1.73 (6) 0.115 (23) 0.154 (14) 0.0032 (12) 0.0596 (11) 0.0015 (10)
5 2.37 (4) 0.064 (21) 0.181 (18) 0.0128 (20) 0.0685 (11) 0.0100 (36)
6 1.87 (11) 0.110 (57) 0.350 (22) 0.0071 (36) 0.1323 (18) 0.0035 (58)
7 2.17 (8) 0.065 (9) 0.232 (91) 0.0089 (70) 0.0961 (10) 0.0104 (92)
8 1.99 (6) 0.043 (23) 0.060 (21) 0.0042 (18) 0.0689 (23) 0.0052 (41)
9 1.69 (8) 0.064 (28) 0.074 (21) 0.0035 (9) 0.1071 (24) 0.0025 (16)
10 1.45 (9) 0.218 (21) 0.188 (10) 0.0033 (14) 0.0512 (9) 0.0013 (8)
Mean6SE 2.0060.12 0.07960.018 0.16760.036 0.007460.0021 0.123260.0327 0.006260.0017
Values are parameter estimates. Numbers in parentheses are estimate precisions expressed as %CV. IVGTT, intravenous glucose tolerance
test; p2 and sk, insulin action parameters.
Fig. 4. TTR clamp estimates of endogenous glucose production (EGP)
obtained with 2-compartment model of Radziuk et al. (20) (s) and
with single-compartment model of Steele et al. (22) (k).
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even if EGP is already almost completely inhibited by the
glucose bolus alone. Resumption to baseline is accompa-
nied by a consistent overshoot of EGP, well above basal,
which is probably driven by the counterregulatory hor-
mones. A comparison of the timing of EGP dynamics
evaluated with the two approaches and of the extent of
EGP overshoot is given in Table 3. It should be noted that
resumption to baseline is rather variable (both in timing
and extent) among individuals, so that endogenous glucose
TTR could not always be kept precisely constant at the
time of resumption (see also Fig. 3). An experimental
design adjustable from subject to subject would in principle
have been valuable, but mass spectrometry measurements
are not feasible on-line.
It is of interest to note that the 2CMM accurately
assesses the dynamics of EGP during the IVGTT but
provides an estimate of basal EGP that is lower than
that independently calculated from [U-13C]glucose data
in the steady state before the IVGTT (EGPb 5 2.47 6
0.15 vs. 1.89 6 0.19 mg·kg21 ·min21, P , 0.05 from
paired, two-tailed t-test). Because basal EGP is the
product of basal glucose clearance times basal glucose
concentration, the underestimation of EGP might re-
flect an underestimation of basal glucose clearance by
the 2CMM analysis. Given that the estimation of basal
glucose clearance by the 2CMM hinges on the final part
of the tracer disappearance curve (when insulin action
is almost negligible and glucose is close to its basal
level), a preliminary question must be addressed before
concluding that the 2CMM provides a biased estimate
of glucose clearance: is it true that glucose clearance in
the final part of the test is similar to that in the pretest?
An answer to this question comes from the analysis of
[U-13C]glucose data: the mean value of glucose clear-
ance that is assessed from the model of Radziuk et al.
(20) in the final part of the IVGTT [calculated as the
product k01(t) ·V1] is not different from that measured
with the same tracer before the IVGTT (2.90 6 0.56 vs.
2.47 6 0.46, not significant). This result allows us to
conclude that for some reason the 2CMM identified
from [6,6-2H2]glucose data underestimates the glucose
clearance achieved at the end of the IVGTT. The next
step is to localize the source of error: is there a problem
in the model or in the [6,6-2H2]glucose data? We have
come to the conclusion that the problem is in the
[6,6-2H2]glucose concentration data. This was proven
by taking the last five to six data points of the [6,6-
2H2]glucose disappearance curve and fitting these data
with a single exponential. We reasoned that, because
insulin action is low in that part of the test and glucose
is close to its basal level, fitting a single exponential
through the latter part of the test is a feasible method
to estimate the slowest eigenvalue (l2) of glucose kinetics,
the one that is mainly responsible for the clearance. We
then compared this data-driven assessment of l2 to the
slow eigenvalue of the 2CMM. We reasoned that if the
2CMM underestimates glucose clearance because of
some model error, the model-based l2 should be lower
than the data-driven l2. We found that the two values
of l2 were virtually identical: l2 from the single-
exponential fitting was 7.9 6 1.6 3 1022/min and from
the 2CMM was 7.2 6 0.8 3 1022/min, r2 5 0.78. This
result indicates both that the 2CMM provides an
estimate of glucose clearance that simply reflects the
final IVGTT [6,6-2H2]glucose data and that [6,6-
2H2]glucose data provide an estimate of glucose clear-
ance lower than that provided by [U-13C]glucose data.
A hypothesis that could account for this observation
is that there is a spurious fraction of [6,6-2H2]glucose
that is recirculating back from the liver, possibly due to
the large resumption of EGP in the second part of the
IVGTT. Glucose-carbon recycling is not a viable option,
because similar values of plasma clearance rate (PCR)
and EGP were estimated with protocols in absence of
carbon tracers.
To gain further understanding of the 2CMM validity,
we attempted to validate its description of the glucose
system by the following procedure. We applied the
known [U-13C]glucose infusion as a known input to the
Fig. 5. EGP estimated by deconvolution (thick line) and by TTR
clamp and 2-compartment model of Radziuk et al. (20) (s). Standard
errors are shown by thin lines and error bars.
Fig. 6. Mean insulin action (min21) in remote insulin compartment
estimated by 2-compartment minimal model. Error bars are stan-
dard deviations.
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2CMM identified from [6,6-2H2]glucose data, and then
we compared the model output with the measured
[U-13C]glucose concentration data. We reasoned that, if
the model identified from the [6,6-2H2]glucose dynam-
ics was able to account for the observed [U-13C]glucose
data, this would support its validity. It can be seen from
the results reported in Fig. 7 that the match between
data and model is quite good except for the final part of
the IVGTT, where the model prediction tends to overes-
timate the observed data. This results in additional
evidence that the 2CMM underestimates glucose clear-
ance in the final part of the IVGTT.
Our results also provide some new insight into the
control of glucose and insulin on EGP suppression. In
the first 40 min after the start of the IVGTT, EGP
shows a bimodal pattern, that is, it is almost totally
inhibited already 15–20 min after the glucose chal-
lenge, then slightly but quickly resumes, and is again
inhibited at ,30–35 min (see Table 3). This second
nadir is in all likelihood due to the exogenous insulin
infusion. It is interesting to note, however, that EGP is
already almost completely suppressed before the insu-
lin injection; thus, it is likely that the insulin injection
pushes further a process that is already fully inhibited.
There is also a very high interindividual variability in
both the timing and the entity of EGP resumption to
baseline, as demonstrated by Table 3 and the error bars
in Fig. 5, and this is confirmed by both methods.
Finally, the time course of EGP allows us to qualita-
tively answer the question of whether EGP inhibition is
triggered directly by plasma glucose concentration.
Apart from the values at 122 and 123 min, which
apparently show a fast EGP inhibition and a quick
return to basal but are in all likelihood spurious (see
earlier discussion), EGP is suppressed slowly with
respect to the time course of plasma glucose concentra-
tion, and this rules out the possibility that EGP inhibi-
tion is directly proportional to plasma glucose. It there-
fore seems more likely that some delayed glucose signal
is responsible for EGP inhibition.
Conclusions
We have validated the estimate of EGP during an
IVGTT obtained by deconvolution against a model-
independent estimate obtained with the TTR clamp.
Both approaches demonstrated almost complete sup-
pression of EGP within 20 min and a high interindivid-
ual variability in the resumption to baseline. The time
course of EGP calculated with both approaches com-
pared very well. Thus the 2CMM, in addition to provid-
ing metabolic indexes of glucose effectiveness and insu-
lin sensitivity, also recovers, when used in conjunction
with deconvolution, EGP time course during the IVGTT;
it therefore is a potentially very useful tool to assess
glucose metabolism in vivo.
Fig. 7. Results of applying the known [U-13C]glucose infusion as a
known input to the 2-compartment minimal model (2CMM) iden-
tified from [6,6-2H2]glucose data. Model prediction (p) is shown
together with experimental [U-13C]glucose concentration data (k
with SD error bars).
Table 3. Individual comparison of salient features of EGP estimates by Radziuk and by the 2CMM
Subject
No.
EGP Estimate
Radziuk 2CMM
TN1 TN2 Tcross DTmax EGPmax TN1 TN2 Tcross DTmax EGPmax
1 126 134 185 77 3.84 126 157 166 23 5.27
2 127 138 185 73 3.91 137 149 178 63 4.63
3 131 141 185 69 2.80 131 157 182 55 2.85
4 131 168 195 63 2.47 129 167 178 32 2.93
5 131 149 168 36 6.34 133 158 168 27 8.47
6 129 153 178 58 2.46 136 164 178 35 2.65
7 131 147 158 38 8.75 125 149 156 31 7.77
8 126 143 178 52 4.96 138 156 168 25 5.32
9 134 158 185 53 2.39 139 181 188 31 3.48
10 129 147 173 48 5.33 139 151 170 38 5.30
Mean6SE 12961 14863 17963 5664 4.3360.65 13362 15963 17363 3664 4.8760.64
2CMM, 2-compartment minimal model; TN1 (min), time of first nadir; TN2 (min), time of second nadir or saddle point; Tcross (min), time at
which endogenous glucose production (EGP) crosses its basal value EGPb; DTmax (min), time elapsed between TN2 and time of maximum EGP
overshoot; EGPmax (mg·min21 ·kg21), maximum EGP overshoot. Note that IVGTT bolus is administered at t 5 120 min. For Radziuk’s
estimate, TN1, TN2, and Tmax are defined only on midpoints of sampling grid, whereas for 2CMM estimate they can lie anywhere within
sampling interval.
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APPENDIX
Appendix A: EGP Estimate from TTR Clamp
Equations of the model of Radziuk et al. (20) for endog-
enous glucose (tracee) kinetics during the IVGTT are
where q1 and q2 denote endogenous glucose masses (mg/kg) in
the first and second compartments, respectively, V1 is the
volume of the accessible pool (dl/kg), Gb is basal (pretest)
glucose concentration, and k21 (min21), k12 (min21), and k01
(min21) are rate parameters describing glucose kinetics.
Equations for the tracer [U-13C]glucose (CII) kinetics are
where the superscript * denotes tracer-related variables, and
CII(0) is different from zero, because by experimental design
[U-13C]glucose has already reached a constant level in plasma
before the initiation of the IVGTT.
A priori identifiable model parameters are V1, k21, k12, and
the basal value of k01(t), k01. Glucose plasma clearance rate
PCR and basal EGP, EGPb, can be directly calculated from the
model parameters as
PCR 5 k 01V1 (A3)
and
EGPb 5 PCR Gb (A4)
respectively.
Let us calculate now EGP from the model of Radziuk et al.
(20). Rearranging the tracee equations, we can derive an
expression for EGP(t)
EGP(t ) 5
dq 1 (t )
dt
1 [k 01 (t) 1 k 21 ]q 1 (t ) 2 k 12q 2 (t ) (A5)
and from the definition of TTR
q 1 (t ) 5
q 1* (t )
ZII (t )
(A6)
Substituting in Eq. A5 the expression for k01 obtained from
Eqs. A1 and A2, we obtain
EGP(t) 5
dq1(t)
dt
1
1
ZII(t) 3Ra*(t) 2
dq1*(t)
dt
1 k12q2*(t)42 k12q2(t)
(A7)
from which, rearranging, we obtain the final expression for
EGP
EGP(t) 5
Ra*(t)
ZII(t)
2
V1Ge(t)
ZII(t)
dZII(t)
dt
1 k12 3q2
*(t)
ZII(t)
2 q2(t)4 (A8)
Now, q*2(t) is the mass of tracer glucose in the accessible pool,
and q2(t) is the mass of tracee glucose in the second, nonacces-
sible pool. Whereas q1(t) (q*1) was calculated at each sampling
point by multiplying the endogenous (exogenous) glucose
concentration by V1, i.e., the volume of the accessible pool,
q2(t) (q*2) was calculated at each sampling point by solving the
first-order differential equation with constant parameters
that describe the kinetics of the Radziuk model’s second pool.
This differential equation has q1(t) (q*1) as forcing input. The
time course (continuous) of q1(t) (q*1) was calculated by linear
interpolation.
Appendix B: EGP Estimate by Deconvolution
The 2CMM is described by Refs. 5, 10, and 24
dq1*(t)
dt
5 2 3kp 1 Rd,0q1(t) 1 k214 q1*(t) 1 k12q2*(t) q1*(0)5 D*
dq2 *(t)
dt
5 k21q1* (t) 2 [k02 1 x(t) 1 k12] q2*(t) q2*(0) 5 0
dx(t )
dt
5 2 p 2x(t ) 1 sk [I (t) 2 Ib] x(0) 5 0
CI(t ) 5
q*1(t )
V1
(B1)
dq1(t)
dt
5 2 [k01(t) 1 k21]q1(t) 1 k12q2(t) 1 EGP(t) q1(0) 5 GbV1
dq 2 (t )
dt
5 k 21q 1 (t ) 2 k 12q 2 (t ) q 2(0) 5 GbV1
k 21
k 12
Ge(t ) 5
q 1(t )
V1
(A1)
dq1*(t)
dt
5 2 [k01(t) 1 k21]q1*(t) 1 k12q2*(t) 1 Ra*(t) q1*(0) 5 CII(0)V1
dq2*(t)
dt
5 k21q1*(t) 2 k12q2*(t) q2*(0) 5 CII(0)V1
k21
k12
CII(t) 5
q1*(t)
V1
(A2)
E292 GLUCOSE PRODUCTION DURING AN IVGTT
 o
n
 O
ctober 10, 2011
ajpendo.physiology.org
D
ow
nloaded from
 
where q*1 and q*2 denote [6,6-2H2]glucose masses in the first
(accessible pool) and second (slowly-equilibrating) compart-
ments, respectively (mg/kg), x(t) is insulin action (min21), I(t)
and Ib are plasma insulin and basal (endtest) insulin, respec-
tively (µU/ml), Gb is basal (endtest) glucose concentration
(mg/dl), q1(t) is cold glucose mass in the accessible pool
(mg/dl), CI(t) is plasma [6,6-2H2]glucose concentration (mg/
dl), D* is the hot glucose dose (mg/kg), V1 is the volume of the
accessible pool (dl/kg), and k21 (min21), k12 (min21), k02
(min21), p2 (min21), and sk (µU·ml21 ·min21) are rate param-
eters describing glucose kinetics and insulin action.
Briefly, the model structure assumes that insulin-indepen-
dent glucose disposal takes place in the accessible pool and is
the sum of two components, one constant (due to, e.g., central
nervous system and red blood cells) and the other propor-
tional to glucose mass. This brings us to the rate constant
describing the irreversible loss from the accessible pool
k 01(t ) 5 kp 1
Rd,0
G(t)V1
(B2)
where G(t) is the glucose concentration in the accessible pool
of volume V1, Rd,0 (mg·kg21 ·min21) is the constant compo-
nent of glucose disposal, and kp (min21) accounts for the
proportional-to-mass term.
To arrive at a priori uniquely identifiable parameters, it is
assumed that 1) in the basal steady state, insulin-indepen-
dent glucose disposal (from compartment 1) is three times
insulin-dependent glucose disposal (from compartment 2),
and 2) Rd,0 is fixed to the experimentally determined value (2)
of 1 mg·kg21 ·min21; this brings us to the following relation
among the model parameters
kp 1
Rd,0
GbV1
5
3k21k02
k02 1 k12
(B3)
The uniquely identifiable parameters of the 2CMM are six:
V1, k21, k12, k02, p2, and sk. From the model parameters, it is
possible to calculate basal EGP
EGPb 5 Rd,0 1 V1 1kp 1 k 21k 02k02 1 k12 2 Gb (B4)
The estimate of EGP during the IVGTT nonsteady state was
obtained by describing with the 2CMM the impulse response
h(t,t) of the glucose system, and by applying a deconvolution
algorithm to invert the integral relation of Eq. 6. The
deconvolution approach used here is nonparametric, is de-
scribed in Refs. 12 and 24, and was previously used to
reconstruct insulin secretion during an IVGTT (21). We refer
to these works for details. An advantage of the method
consists in the availability of a new statistically sound
criterion, based on maximum likelihood, for the choice of the
regularization parameter.
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